NVIDIA insiders are selling in Q1, but investors shouldn't be worried because share-based compensation is in play, and institutions and analysts are buying.
Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.
Three companies have come on a list of potential buy-and-hold candidates for the rest of the year and forward; their prices and upside make sense today.
D-Wave Quantum unveiled a second major technological breakthrough in late March with the potential to upend the blockchain space; why did shares plunge after?
SoFi's volatility presents a complex investment decision as growth initiatives and market uncertainties create a complex outlook for investors to consider.
FedEx's weaknesses offset its strengths and set it up for lower stock prices after the Q3 release and guidance update. Analysts are lowering their targets.
Despite RKLB’s 44% drop from its 2024 peak, analysts remain bullish with a Moderate Buy rating and a $23.06 price target, signaling a potential upside.
Palantir stock is finding support at a key level after announcing a deal with R1 to improve healthcare financial operations; institutions may have to buy
BYD's new 5-minute EV charging platform electrifies the market as investors respond enthusiastically to the technology and push shares to record highs.
Amazon is down 20%, but analysts see huge upside. With strong earnings and bullish technicals, this pullback may be a rare long-term buying opportunity.
Broadcom shares recently got a big boost after the company's strong earnings. It continues to position itself as one of the top stocks in AI investing.
Tesla is down 50% in three months, but analysts are split. Some see more downside, while others see 150% upside. With its RSI at 29, is a reversal finally near?
Why does Steve Reitmeister believe the S&P 500 (SPY) needs to be back above 5,747 by 3/31 or it spells trouble for investors? Read on below for the full answer.